As a growing number of Suboxone tooth decay lawsuits continue to be filed in the MDL, judge is considering arguments raised by the drug maker that the claims are preempted by federal law.
Reports suggest that Suboxone dental decay problems are still causing users to experience tooth fractures, infections, bone loss and jaw issues.
Indivior claims federal law prevented it from updating the Suboxone tooth decay warnings before June 2022, indicating that thousands of lawsuits should be dismissed.
Census of all Suboxone lawsuits will help the parties determine which tooth decay claims could be used as representative samples in early bellwether trials.
Suboxone tooth decay data will be produced as the parties work to exchange information needed to select a representative group of lawsuits for early bellwether trials.
Lawyers will meet with the MDL judge presiding over all Suboxone tooth decay lawsuits on October 4 and 5, to finalize information needed to select the first cases for bellwether discovery and trials.
A report will be submitted next week about the status of investigations into thousands of Suboxone dental injury lawsuits filed on a bundled complaint.
Lawyers are expected to discuss how to select a representative group of claims involving Suboxone dental injuries during a meeting with the Court on October 5.
In response to a motion to dismiss filed by Indivior, plaintiffs indicate that the drug maker knew about the risk of tooth decay problems from Suboxone long before the FDA required an update to the label warning.
Suboxone manufacturer attempts to argue that failure to warn and design defect claims over tooth decay risks should be preempted by federal law.
